25 Organisations

Institutional Investors

Institutional investors — pension funds, endowments, and family offices — with psychedelic portfolio exposure.

Organisations: 25
Countries: 4

Investor Finder

Company Context

Showing 25 of 25

Adage Capital Management
Adage Capital Management is a Boston-based institutional investment manager with deep roots in public equity investing and selective private-company participation. It is not publicly positioned as a psychedelics specialist. Its relevance to psychedelic medicine comes from confirmed exposure to Beckley Psytech and the 2025 atai/Beckley transaction financing. The record is strongest when framed as broad institutional healthcare capital entering the space opportunistically.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Company-Led Drug Development & Commercialization
Portfolio Signals
Beckley Psytech
Series B · $80 million · Aug 16, 2021
AtaiBeckley
Concurrent private placement · $30.0M · Jun 2, 2025
ADAR1 Capital Management
ADAR1 Capital Management is an Austin-based investment manager focused on public and private equity investments in life sciences and biotechnology. Public adviser and investor materials point to a specialist healthcare and biotech orientation. ADAR1's relevance to psychedelic medicine is source-backed through atai's 2025 private placement. The record is useful for mapping public-market and crossover healthcare capital around psychedelic mental-health drug development.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Public MarketsGrowth / Late StageNonprofit / grant-backed
Company-Led Drug Development & Commercialization
Portfolio Signals
atai Life Sciences
Private placement financing · approximately $50 million · Jul 1, 2025
AtaiBeckley
Portfolio stakeholder
Ally Bridge Group
Ally Bridge Group is a global healthcare investment management firm investing across private and public life-science markets. Its website emphasizes cross-market healthcare investing, with teams and offices spanning New York and Hong Kong. Within psychedelic medicine, Ally Bridge is relevant through atai's 2025 private placement. This makes it a healthcare crossover investor in the sector, not a dedicated psychedelic investor.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Company-Led Drug Development & Commercialization
Portfolio Signals
atai Life Sciences
Private placement financing · approximately $50 million · Jul 1, 2025
AtaiBeckley
Portfolio stakeholder
Ark Invest
ARK Invest, legally ARK Investment Management LLC, is an active investment manager founded by Cathie Wood in 2014. It is based in New York, United States, and focuses on disruptive innovation across public markets, with some private-market exposure through ARK Venture Fund. ARK has published dedicated research on psychedelic therapeutics and the field’s clinical and commercial potential. Its public research and thematic investment approach make it a relevant institutional stakeholder for psychedelic drug development companies, especially those advancing novel therapies into clinical and public-market stages.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
Berenberg
Berenberg, legally Berenberg, Gossler & Co., is a long-established private bank and financial services group founded in 1590 in Hamburg. It operates across investment banking, asset management, corporate banking, and wealth management, and describes itself as one of Europe’s leading private banks. In the psychedelic ecosystem, Berenberg matters mainly as a public-markets and healthcare-capital-markets participant rather than a dedicated psychedelic specialist. Its published equity and healthcare strategies focus on growth-oriented companies, and its investment banking business has supported multiple life sciences and biotech financings, including healthcare-sector equity transactions.
View Profile
Investor Category
Institutional Investors
HQ
HQ: Germany
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
BlackRock
BlackRock is a global asset manager and fiduciary investor founded in 1988 in New York. Its investment stewardship business engages with public companies and votes on behalf of clients across index and active portfolios. Public BlackRock location pages list its New York office at 50 Hudson Yards, New York, NY 10001, United States. In the psychedelic ecosystem, BlackRock is relevant primarily as a large public-markets stakeholder rather than a dedicated psychedelic specialist. Its stewardship and portfolio activities span global public companies and multiple asset classes, so it may appear as a shareholder in listed life sciences or healthcare names even though it does not advertise a public psychedelic focus.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
BTIG
BTIG is a global financial services firm that provides institutional sales and trading, research, and investment banking services. Its website describes the firm as serving institutional and corporate clients across public markets, with a strong healthcare banking presence. The firm’s New York office at 65 East 55th Street is the address most prominently listed on BTIG’s site. In the psychedelic ecosystem, BTIG is relevant primarily as a healthcare and capital markets intermediary rather than a dedicated psychedelic investor. BTIG’s healthcare investment banking coverage includes biotechnology and pharmaceuticals, which can overlap with psychedelic drug-development companies if they seek public-market financing, strategic advice, or aftermarket support.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
Canaccord Genuity
Canaccord Genuity Group Inc. is a global independent investment dealer with capital markets and wealth management operations, including investment banking and advisory services for public and private companies. Public company filings identify its head office in Vancouver, British Columbia, Canada. In the psychedelic ecosystem, Canaccord Genuity is relevant mainly as a capital-markets adviser rather than a dedicated psychedelic specialist. Its published transactions show activity in adjacent areas such as cannabis, healthcare, and public growth financings, which can intersect with psychedelic companies that access public markets or pursue strategic capital raises.
View Profile
Investor Category
Institutional Investors
HQ
HQ: Canada
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
Cantor Fitzgerald
Cantor Fitzgerald is a global financial services firm founded in 1945 that provides investment banking, capital markets, fixed income, equities, prime services, research, asset management, and related services. Its website identifies it as a privately owned firm with a broad institutional and public-markets orientation, and its headquarters is in New York, New York, United States. For the psychedelic ecosystem, Cantor Fitzgerald appears relevant mainly as a capital-markets and financing intermediary rather than a dedicated psychedelic investor. Public materials show activity in investment banking, SPACs, PIPE placements, and asset management, which can make it relevant to public psychedelic companies seeking listings, financings, or coverage, but there is no public evidence of a specific psychedelic focus.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
Cowen
Cowen is a U.S.-based diversified financial services firm and institutional investor platform that has historically combined investment banking, research, sales and trading, prime brokerage, and investment management. Public filings describe Cowen as founded in 1918 and headquartered in New York, with principal executive offices at 599 Lexington Avenue in New York City. In the psychedelic ecosystem, Cowen matters mainly as a broad healthcare capital provider rather than a dedicated psychedelic investor. Its public investment management strategies have included healthcare royalties, private healthcare investing, and public and private healthcare strategies, which can place it near adjacent biotech and neuroscience opportunities even though no public psychedelic focus is stated.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
EF Hutton
EF Hutton is a global full-service investment bank focused on middle-market and emerging growth companies, with public and private offerings across debt and equity capital markets. Its website lists product offerings including investment banking and advisory, private credit, asset-backed finance, credit tenant lease and ground lease finance, private equity, and project and infrastructure finance. Public materials describe the firm as headquartered in New York, New York. In the psychedelic ecosystem, EF Hutton is relevant primarily as a capital markets and research intermediary rather than as a dedicated psychedelic specialist. Public materials show the firm has provided sell-side research on small and mid-cap companies and has covered or advised companies in the broader mental health and biotech space, which can overlap with public psychedelic issuers, but its public positioning remains industry-agnostic rather than explicitly psychedelic-focused.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
EF Hutton Acquisition Corporation I
SPAC IPO · $115,000,000 · Sep 1, 2022
Evercore
Evercore is a publicly traded global independent investment banking advisory firm, not a venture fund or direct psychedelic investor. It was founded in 1995 and is headquartered in New York, United States, with offices and affiliate offices across major financial centers in North America, Europe, the Middle East, and Asia. In the psychedelic ecosystem, Evercore’s relevance is mainly as a capital markets and strategic advisory firm rather than a specialist life-sciences investor. Its healthcare and biotech coverage, private capital markets, and public-company advisory work can make it relevant to psychedelic companies seeking M&A advice, financing, or public-market transactions.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
H.C. Wainwright & Co.
H.C. Wainwright & Co., LLC is a New York-based full-service investment bank offering investment banking, equity research, sales and trading, strategic advisory, and corporate access services. The firm says it serves public and private growth companies across multiple sectors and regions, and its office is at 430 Park Avenue, New York, New York 10022. In the psychedelic ecosystem, H.C. Wainwright matters primarily as a capital-markets and conference platform rather than as a dedicated psychedelic specialist. Its public materials show a strong life sciences and biotechnology orientation, and its events have included companies such as Awakn Life Sciences and Cybin in the broader psychedelics space.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
Jefferies
Jefferies is a global full-service investment banking and capital markets firm, rather than a specialist psychedelic investor. Its public materials describe the firm as operating worldwide, with principal offices in New York and regional headquarters in London and Hong Kong. In the psychedelic ecosystem, Jefferies matters mainly as a broad capital-markets and research platform that has published industry thought leadership on psychedelics and mental health. Its public primer on mental health and psychedelics notes active investor interest in the space and discusses public and private psychedelic drug-development companies, but it does not establish Jefferies as a dedicated psychedelic-focused fund.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
Johnson & Johnson
Johnson & Johnson is a publicly traded global healthcare company rather than a venture fund or dedicated asset manager. Its business spans pharmaceuticals and medical technology, and the company is based in New Brunswick, New Jersey, United States. In the psychedelic ecosystem, Johnson & Johnson matters mainly through its neuroscience and psychiatry-adjacent pharmaceutical activity rather than as a standalone investor. Its acquisition of Intra-Cellular Therapies, a CNS-focused biopharma, shows continued interest in neuropsychiatric therapeutics and related clinical-stage assets.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Academic & Non-Profit Research
Portfolio Signals
Public portfolio context is limited.
Maxim Group
Maxim Group LLC is a New York-based full-service investment bank, securities firm, and wealth management platform that provides investment banking, capital markets, research, sales and trading, and private wealth services. Public sources list its headquarters in New York, NY, with offices in Florida, New Jersey, and Connecticut. In the psychedelic ecosystem, Maxim Group matters primarily as a Wall Street coverage and capital-markets participant rather than as a dedicated psychedelic investor. Its research platform has covered multiple psychedelic-focused public companies, and its investment-banking business also works across healthcare and biotechnology, which places it near the financing activity around the sector.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
Morgan Stanley
Morgan Stanley is a global financial services firm and institutional investor founded in 1935. Public Morgan Stanley pages describe the firm as headquartered in New York, with worldwide offices and clients across institutions, corporations, governments, and individuals. In the psychedelic ecosystem, Morgan Stanley’s relevance is mostly indirect: its investment management arm covers global public and private markets, and its published research has discussed psychedelics as an emerging theme in healthcare and investing. The firm does not present a public psychedelic investment focus, but its broad capital-markets and growth-investing platform could make it relevant to late-stage life sciences and adjacent healthcare companies.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
Oppenheimer
Oppenheimer & Co. Inc. is a global financial institution offering wealth management, capital markets, and investment banking services. Its institutional-facing businesses include equity research, investment banking, and institutional services, and its principal place of business is in New York, New York. In the psychedelic ecosystem, Oppenheimer matters primarily as a generalist capital-markets and healthcare finance platform rather than a specialist psychedelic investor. Its healthcare research and investment banking coverage spans biotechnology, biopharmaceuticals, specialty pharmaceuticals, and emerging-growth companies, which can make it relevant to public and private life-sciences issuers that overlap with psychedelic drug development.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
Orbimed Advisors
OrbiMed Advisors is a global healthcare investment manager that invests across the life sciences and healthcare sectors, from seed-stage private companies to large publicly traded companies. Its platform spans public equity, private equity, and private credit/royalty strategies, and the firm says its investment business was founded in New York City in 1989. For the psychedelic ecosystem, OrbiMed matters mainly as a large, healthcare-focused capital provider rather than as a specialist psychedelic backer. Its public materials describe broad investing across biopharmaceuticals, medical devices, diagnostics, and healthcare services, with capital deployed across the full company lifecycle and capital structure, which makes it relevant to psychedelic companies only where they fit broader drug development or healthcare themes.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
Otsuka
Otsuka Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company within the Otsuka group, focused on creating and commercializing medicines and nutraceutical products. Its corporate profile lists its head office in Chiyoda-ku, Tokyo, Japan. The company describes itself as a total healthcare company with global operations and collaboration across academia and venture partners. In the psychedelic ecosystem, Otsuka is relevant because it has moved into adjacent neuropsychiatric and rapid-acting treatment areas through acquisitions and research collaborations. In 2025 it announced a joint research agreement with Keio University on infrastructure development for the social implementation of psychedelics in Japan, and in 2026 it announced and then completed its acquisition of Transcend Therapeutics, whose lead program TSND-201 is described as a rapid-acting neuroplastogen for PTSD.
View Profile
Investor Category
Institutional Investors
HQ
HQ: Japan
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Company-Led Drug Development & Commercialization
Portfolio Signals
Mindset Pharma
strategic acquisition · undisclosed · Sep 1, 2023
Transcend Therapeutics
strategic acquisition · $1.225 billion potential consideration · Mar 27, 2026
Perceptive Advisors
Perceptive Advisors is a long-established life sciences investment manager based in New York. Its public materials describe a multi-strategy platform spanning life sciences, credit, capital solutions, and venture capital, with an emphasis on scientific diligence. In psychedelic medicine, Perceptive's role is healthcare-adjacent rather than dedicated. The firm has a confirmed COMPASS Pathways financing record, which supports inclusion without implying that psychedelics are a central thematic focus for the platform.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Multi-StagePublic MarketsNonprofit / grant-backed
Company-Led Drug Development & CommercializationEducational Platforms & Resources
Portfolio Signals
COMPASS Pathways
Series B · $80m · Apr 27, 2020
Pura Vida Investments
Pura Vida Investments is a New York-based healthcare-focused investment firm and SEC-registered investment adviser that operates as a hedge fund / investment manager. Public sources describe it as market-neutral and oriented toward healthcare and life sciences, with activity across biotech, medical technology, diagnostics, and related therapeutics. In the psychedelic ecosystem, Pura Vida matters mainly as a public-market and crossover healthcare investor rather than a dedicated psychedelics specialist. It has been named in funding rounds for atai Life Sciences, one of the sector’s best-known public psychedelic companies, which suggests exposure to mental-health and psychedelic-adjacent drug development. Public materials place Pura Vida Investments in the New York area and describe it as a healthcare-focused, market-neutral investor with a broad life-science remit. Its publicly visible psychedelic relevance is indirect but meaningful: it has participated in at least one major atai Life Sciences financing, aligning the firm with the public-market side of psychedelic and mental-health therapeutics investing.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
atai Life Sciences
Series D · undisclosed · Mar 3, 2021
RA Capital Management
RA Capital Management is a large, multi-stage healthcare and life-sciences investment manager that funds and builds companies across a wide development spectrum. Its public materials stress evidence-based investing, company formation, and deep scientific diligence. For psychedelic medicine, RA Capital is relevant because it publicly lists Delix Therapeutics in its venture portfolio and Delix financing materials identify RA as a lead investor in the company's Series A. This is a strong psychedelic-adjacent record, while RA remains best framed as a broad life-sciences investor.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
SeedSeries A/BGrowth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Company-Led Drug Development & Commercialization
Portfolio Signals
Delix Therapeutics
Series A · $70 million · Sep 27, 2021
Roth Capital
Roth Capital Partners, LLC is a relationship-driven investment bank serving growth companies and their investors. It is headquartered in Newport Beach, California, with a global trading floor in Stamford, Connecticut. ROTH’s healthcare platform provides financing and strategic advisory services for public and private life sciences companies, including IPOs, follow-on offerings, PIPEs, registered directs, and confidentially marketed public offerings. In the psychedelic ecosystem, that makes it relevant primarily as a capital markets and advisory participant rather than a dedicated psychedelic specialist.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
Stifel
Stifel is a U.S.-based diversified wealth management and investment banking firm with a corporate headquarters in St. Louis, Missouri. It serves individuals, institutions, and corporations through brokerage, research, investment banking, and related financial services. In the psychedelic ecosystem, Stifel is mainly relevant as a healthcare and biopharma capital-markets participant rather than a dedicated psychedelic specialist. Its public materials show active coverage of life sciences and biopharma, including venture banking and capital-raising activity in the sector, which makes it a potential advisor or financing counterparty for psychedelic drug developers as they move through public and late-stage markets.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
Growth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.

Investor Landscape

Explore investor stakeholders by type, funding stage, and sector focus across the psychedelic ecosystem.

Investor Types

Institutional Investors25

Venture Capital1

Stage Focus

Public Markets25Growth / Late Stage24Multi-Stage24Seed1Series A/B1

Focus Areas

Drug Development25Clinical Infrastructure2Manufacturing & Supply Chain2Digital Therapeutics & Platforms1

Institutional Investors

Company Context

Investor Landscape

Investor Types

Stage Focus

Focus Areas

Company

Product

Legal

Company Context